News

CVD risk persists for 40 years in Hodgkin’s survivors

View on the News

Rise to the challenge

Primary care physicians must rise to the challenge of promoting the health of cancer survivors. Previous research suggests that many are not comfortable caring for this patient population and report knowledge gaps regarding the additional screening and surveillance they require. Most patients in the study by Ms. van Nimwegen and her colleagues were not screened for CVD.

Asking just a few key questions will identify these patients: What kind of cancer did you have? How old were you at diagnosis? Did you receive any chest radiotherapy? Did you receive doxorubicin (which they may know only by the brand name Adriamycin)? Our clinical experience has been that patients typically know the answers to these basic questions, which is a simple way of identifying those at increased risk.

Dr. Emily Tonorezos is with the department of medicine at Memorial Sloan Kettering Cancer Center and at Cornell University, both in New York. Dr. Linda Overholser is with the division of general internal medicine at the University of Colorado at Denver, Aurora. They reported having no relevant financial disclosures. These comments are adapted from an accompanying editorial written by Dr. Tonorezos and Dr. Overholser (JAMA Intern. Med. 2015 April 27 [doi:10.1001/jamainternmed.2015.1187]).


 

FROM JAMA INTERNAL MEDICINE

References

People who survive Hodgkin’s lymphoma in adolescence or young adulthood remain at very high risk for cardiovascular disease for at least 40 years – the longest period for which they have been followed, according to the results of a retrospective cohort study of more than 2,500 patients.

Until now, follow-up studies of such patients “rarely exceeded 20-25 years,” before most survivors reached the age at which cardiovascular disease (CVD) becomes commonplace in the general population. To compare CVD rates between survivors and the general population at later ages, investigators examined the medical records of 2,524 individuals who survived 5 years or more after being treated for Hodgkin’s lymphoma as adolescents or young adults at five Dutch medical centers between 1965 and 1995.

A total of 81% of the cohort had received mediastinal radiotherapy and 31% had received anthracycline-containing chemotherapy. After 5-47 years of follow-up, 797 of these patients experienced 1,713 cardiovascular events. The most frequently occurring events included 401 coronary heart disease events (such as myocardial infarction and angina pectoris), 374 valvular heart disease events, and 140 heart failure events (such as cardiomyopathy and congestive heart failure), Frederika A. van Nimwegen of the department of epidemiology, the Netherlands Cancer Institute, Amsterdam, and her colleagues wrote in JAMA Internal Medicine on April 27 (doi:10.1001/jamainternmed.2015.1180).

Compared with the general population, Hodgkin’s survivors had a 3.2-fold higher standardized incidence ratio (SIR) of developing coronary heart disease and a 6.8-fold higher SIR of developing heart failure, corresponding to 70 excess cases of coronary heart disease and 58 excess cases of heart failure per 10,000 person-years.

These risks were significantly higher for survivors than for the general population at all ages, but patients who had been diagnosed and treated before the age of 25 years were at particularly elevated risk: they carried a 4.6- to 7.5-fold higher risk of coronary heart disease and a 10.9- to 40.5-fold higher risk of heart failure. At 40 years after Hodgkin’s diagnosis and treatment, the cumulative incidence of any type of CVD was 50%, the investigators wrote. Both survivors of Hodgkin’s lymphoma and their physicians should be aware that these patients remain at substantially increased cardiovascular risk throughout their lives, Ms. Van Nimwegen and her colleagues wrote.

This study was supported by the Dutch Cancer Society. Ms. van Nimwegen and her colleagues reported having no financial disclosures.

Recommended Reading

Studies Clash on Cardiac Effects of TKIs in Kidney Cancer
MDedge Hematology and Oncology
2-D Echo Is Inadequate Cardiomyopathy Screen in Childhood Cancer Survivors
MDedge Hematology and Oncology
Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
MDedge Hematology and Oncology
Cardiac Toxicity Not Seen 25 Years after Breast Radiation
MDedge Hematology and Oncology
Guidelines issued on radiation-induced heart disease
MDedge Hematology and Oncology
Heart irradiation is lower with contemporary breast radiotherapy
MDedge Hematology and Oncology
Palliative care shortens ICU, hospital stays, review data show
MDedge Hematology and Oncology
Androgen-deprivation therapy linked to cardiac death
MDedge Hematology and Oncology
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Hematology and Oncology
Who will get cancer treatment-induced cardiotoxicity?
MDedge Hematology and Oncology